Beijing – October 13, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.
Likang co-founder joins October 21 oncology panel
Shannon Cheung, Co-Founder and Vice Chairman of Likang, will speak on the panel "The Future of Cancer" on October 21. The session will cover precision oncology and the translation of innovative cancer treatments into clinical practice. It forms part of the summit's Abu Dhabi Blueprints series and will examine the roles of research, investment, policy, and international collaboration in getting new therapies to patients.
Abu Dhabi health authority expects 175 exhibitors from about 100 countries
The Department of Health – Abu Dhabi (DoH) convenes the summit, which draws policymakers, researchers, clinicians, investors, and industry leaders. Its theme, "To Sense Is to Predict," centers on artificial intelligence, genomics, advanced diagnostics, and personalized healthcare. Organizers expect participants from approximately 100 countries and more than 175 exhibiting organizations.
LK101 is a personalized neoantigen mRNA-DC vaccine
Likang's proprietary AI-powered neoantigen discovery platform identifies and prioritizes patient-specific tumor neoantigens. The platform feeds a pipeline of personalized therapeutic cancer vaccines and neoantigen-specific T-cell therapies. LK101, the lead investigational candidate, is a personalized neoantigen mRNA-DC therapeutic cancer vaccine.
Likang targets Abu Dhabi's precision medicine ecosystem for partnerships
At the summit, Likang will present its technology platform, its clinical development programs, and its experience moving personalized immunotherapies from research into clinical development. The company plans to meet international healthcare institutions, researchers, and industry partners, with a focus on Abu Dhabi's growing precision medicine ecosystem, to explore scientific and clinical collaboration.